SYBLEU Inc (SYBE) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1034 THROGGS NECK EXPRESSWAY BRONX, NY 10465 |
| State of Incorp. | WY |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2023 MRQ | 6/30/2023 | 6/30/2022 | 6/30/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 4 | 67 | 14 | |||
| Cash and cash equivalents | 4 | 67 | 14 | |||
| Prepaid expense | 16 | |||||
| Other current assets | ||||||
| Total current assets: | 19 | 67 | 14 | |||
| Noncurrent Assets | ||||||
| Intangible assets, net (including goodwill) | 2 | |||||
| Intangible assets, net (excluding goodwill) | 2 | |||||
| Prepaid expense | 9 | |||||
| Other undisclosed noncurrent assets | 302 | 10 | 184 | |||
| Total noncurrent assets: | 311 | 10 | 185 | |||
| TOTAL ASSETS: | 330 | 76 | 200 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 16 | 11 | 22 | |||
| Taxes payable | ✕ | ✕ | 11 | 21 | ||
| Accrued liabilities | 16 | 0 | 0 | |||
| Debt | 178 | |||||
| Due to related parties | ✕ | 9 | ||||
| Other undisclosed current liabilities | 38 | 153 | ||||
| Total current liabilities: | 231 | 165 | 31 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 300 | |||||
| Long-term debt, excluding current maturities | 300 | |||||
| Liabilities, other than long-term debt | 140 | 9 | ||||
| Due to related parties | ✕ | 140 | 9 | |||
| Other undisclosed noncurrent liabilities | 150 | 22 | 164 | |||
| Total noncurrent liabilities: | 450 | 162 | 173 | |||
| Total liabilities: | 681 | 326 | 204 | |||
| Equity | ||||||
| Equity, attributable to parent | (351) | (250) | (5) | |||
| Common stock | 1 | 1 | 1 | |||
| Additional paid in capital | 179 | 100 | 100 | |||
| Accumulated deficit | (531) | (351) | (106) | |||
| Other undisclosed equity, attributable to parent | ||||||
| Other undisclosed equity | 0 | |||||
| Total equity: | (351) | (250) | (5) | |||
| TOTAL LIABILITIES AND EQUITY: | 330 | 76 | 200 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2023 TTM | 6/30/2023 | 6/30/2022 | 6/30/2021 | ||
|---|---|---|---|---|---|
| Revenues | 12 | 12 | 4 | ||
| Cost of revenue | (56) | (47) | (54) | ||
| Gross profit: | (45) | (36) | (50) | ||
| Operating expenses | (105) | (21) | (38) | ||
| Other operating expense, net (Other Expenses) | (14) | ||||
| Other undisclosed operating income (loss) | (0) | 14 | |||
| Operating loss: | (149) | (56) | (88) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (31) | (189) | 8 | ||
| Loss from continuing operations before income taxes: | (180) | (245) | (80) | ||
| Income tax expense | (21) | ||||
| Loss from continuing operations: | (180) | (245) | (102) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (245) | (102) | |
| Net loss available to common stockholders, diluted: | (180) | (245) | (102) | ||
Comprehensive Income ($ in thousands)
| 12/31/2023 TTM | 6/30/2023 | 6/30/2022 | 6/30/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (180) | (245) | (102) | ||
| Comprehensive loss, net of tax, attributable to parent: | (180) | (245) | (102) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.